| Drug Name |
Quinapril hydrochloride |
| Drug ID |
BADD_D01891 |
| Description |
Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers.[A184844]
Quinapril was granted FDA approval on 19 November 1991.[L8420] A combination tablet with [hydrochlorothiazide] was also approved on 28 December 1999.[L8423] |
| Indications and Usage |
For the treatment of hypertension and as adjunct therapy in the treatment of congestive heart failure. May also be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
C09AA06 |
| DrugBank ID |
DB00881
|
| KEGG ID |
D00459
|
| MeSH ID |
D000077583
|
| PubChem ID |
54891
|
| TTD Drug ID |
D0I7SZ
|
| NDC Product Code |
65862-617; 65862-368; 65862-619; 15308-0500; 65862-618; 50090-2117; 63629-7934; 50090-2116; 65862-620; 17404-0015; 0071-0535; 63827-1009; 0071-0527; 63187-874; 0071-0530; 0071-0532 |
| Synonyms |
Quinapril | 2-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid | Accupril | CI 906 | CI-906 | Quinapril Hydrochloride | PD 109452-2 | PD 109452 2 | PD 1094522 | PD-109,452-2 | PD 109,452 2 |
